Immune Regulatory 1 Cells: A Novel and Potent Subset of Human T Regulatory Cells

A subset of T regulatory cells (Tregs), identified by TIRC7 (T cell immune response cDNA 7) expression is designated as Immune Regulatory 1 Cells (IR1 cells). TIRC7 is an immune checkpoint inhibitor, co-localized with the T- cell receptor, HLA-DR and CTLA-4 during T-cell activation, which delivers regulatory signals via binding to its ligand, HLA-DR α2 domain. IR1 cells express FOXP3, and multiple other markers associated with immune suppression. They constitute as much as 10% of Tregs. IR1 cells strongly inhibit proliferation in mixed lymphocyte reactions, where they express high levels of IL-10. Ex vivo expansion of Tregs over 2 weeks in the presence of an agonist TIRC7 antibody disproportionately expands the IR1 Treg subset, while maintaining high expression of suppressive markers including CD39, IL-10, LAP and GARP. Ex vivo expanded IR1 cells are a potent, homogeneous, stable set of suppressor Tregs with the potential to modulate immune dysregulation. The characteristics of IR1 cells suggest a therapeutic advantage over polyclonal Tregs for therapeutic interventions. Early restoration of immune homeostasis using IR1 cells has the potential to fundamentally alter the natural history of conditions characterized by abnormalities in the T regulatory cell compartment.


INTRODUCTION
Thymus-derived T lymphocytes form the basis of cellular immunity in humans. T cells perform a wide range of functions, including the initiation and maintenance of immune response and memory. CD4+ regulatory T cells play an essential role in immunological homeostasis (1,2). Treg immunosuppressive properties have generated interest for their therapeutic potential in a wide range of clinical indications. Expression of CD4 and CD25 were early indicators of a subset of regulatory cells able to transfer tolerance in autoimmune conditions. Expression of the transcription factor FOXP3, encoded by an X-linked gene (3), and low expression of CD127 are also markers of T suppressive function (4). Tregs, defined by marker phenotype CD4+CD25+ CD127loFOXP3+, make up less than 10% of human CD4+ cells (1) and are heterogeneous. It is important to identify functional subgroups to optimize therapeutic Treg cell interventions (5,6). To this end, we have investigated the association of key measures of T-regulatory cell suppressive activity, and the presence of the immune surface marker TIRC7, in human T-regulatory cells.
We have previously identified TIRC7 (T-cell immune response cDNA 7) (7,8), a multimembrane spanning protein, co-localized with the T cell receptor, HLA-DR and CTLA-4 (9, 10), which is induced within hours of T cell activation (11). TIRC7, also referred to as TCIRG1 (T cell immune regulator 1), and its splice variant OC116, expressed in bone tissues, share the same chromosomal location at 11q13.4-q13.5 (12). TIRC7 induction is largely restricted to activated lymphocytes and lymphoid tissue (13). The natural ligand of TIRC7 is the HLA-DRa2 domain (14). TIRC7 disruption in mice leads to a hyperproliferative phenotype of T and B cells with an increase in the effector memory cell population (8). Previous work has shown that activation of TIRC7 by soluble HLA-DRa2 or by an agonist anti-TIRC7 antibody, initiates an intracellular signaling cascade, which inhibits tbet and Stat4, thereby decreasing Th1 and Th17 proinflammatory cytokine expression, and at the same time increases levels of immune suppressive molecules, including IL-10, CTLA-4, and caspases 9 and 7 (11,14). Activation of TIRC7 signaling induces antigen specific anergy and inhibits proliferative response in T cells (15).
TIRC7 appears to play a key role in graft versus host disease (16), allograft rejection (17) and autoimmune disorders (9). During solid organ transplant rejection, TIRC7 expression is increased in the allograft and decreased in peripheral blood lymphocytes (18). This dynamic is consistent with highly specialized expression in areas of ongoing inflammation and immune activation. TIRC7 agonist antibodies are effective in prevention and treatment of autoimmune disease and solid organ transplant rejection in preclinical animal models (17). Murine TIRC7+ CD4+CD25lo IL-10 secreting cells were described by Wakkach et al. (19) Although they exhibited immune suppression in vitro and in vivo, the phenotype of these murine TIRC7+ cells differ from human IR1 cells. Human TIRC7+ T regulatory cells and their characteristics have not previously been elucidated.
Here, we present the phenotype and function of a T-regulatory cell subset, designated IR1 cells, a novel, homogenous, suppressive TIRC7+ T regulatory cell subset. IR1 cells express multiple surface markers associated with immune suppression and cell migration. We have developed agonist antibodies to TIRC7 to expand IR1 cells ex vivo, an essential step towards exploring clinical applications.
IR1 cells represent a small proportion of all PBMC ( Figure 1A). Tregs represent a mean of 7% of total CD4 cells. IR1 cells in turn, constituted a mean of 5.4% (range 3.3-11) of all Tregs. Circulating IR1 cells represent only about 0.4% of all CD4 cells, with a relatively small inter-individual variability in frequency among the healthy subjects studied here (range 0.2-0.7%) ( Table 1). IR1 cells had a mean frequency of 8 per 10,000 PBMC (range 5-13) while the mean frequency of IR1neg Tregs is much higher (150 per 10,000 PBMC, (range 86-250). Per 10,000 PBMC, the mean within-subject ratio of IR1neg Tregs to IR1 cells was 21 (range 8 to 47). Within healthy subjects, the frequency of IR1 cells was not correlated with the frequency of IR1neg Tregs per 10,000 PBMC. TIRC7+ Tregs (IR1 cells) are shown mapped to the CD25 hi-med compartment of total Treg cells ( Figure 1B).

IL-2 Disproportionally Expands IR1 Cells
Treg cells were activated ex vivo by incubation with IL-2 for 72 hours for 8 of the subjects. IL-2 incubation disproportionally increased IR1 cells. Two overlaid histograms (blue FMO control, red TIRC7 panel, Figure 1C) show the TIRC7 expression of Tregs from a healthy donor directly after isolation (t0) and after IL-2 activation (t72h). This corresponds to the FOXP3+ population of resting and activated Tregs ( Figure 1D). Activation of Tregs with IL-2 for 72h resulted in a substantial increase in the proportion of IR1cells (17%) in comparison to baseline (8%).
The IR1 cell phenotype was found to be distinct and stable. After activation, IR1 cells continued to demonstrate stable, high expression of FOXP3. In the example shown ( Figure 1D and Supplementary  Figures 1.2, 1.3), at t=0h, among CD25hiFOXP3+cells, 6.56% were TIRC7+. After in vitro expansion with IL-2 (1,000 UI/ml) for 72h, IR1 cells made up 14.2% of CD25hiFOXP3+cells.
The surface markers expressed in IR1 cells were generally higher on CD45RAlo IR1 cells ( Figures 1I, J).

IR1 Cells Combine Homing and Anti-Inflammatory Markers on Their Surface
After 72h of IL-2 stimulation, Tregs were stained with antibodies against surface molecules and phenotyped using FACS analysis. IR1 cells proved to be phenotypically distinct from IR1neg Tregs with respect to multiple markers associated with immune suppressive activity. Table 3 shows percent surface expression (median and inter-quartile ranges) of key surface markers for IR1 cells and IR1neg Tregs after 72h of IL-2 ex-vivo exposure. Highly significant differences were noted for CD62L, LAP, IL-10, CTLA-4, HLA-DR, GARP, Helios (p<0.01) and for ICOS, CD39, CCR7(p<0.05). Violin plots of these data ( Figure 2A) make clear the distinct overall patterns of surface expression and the differences in individual markers frequency for IR1 cells versus IR1neg Tregs. Representative flow cytometry examples are shown in Figure 2B.
While the above-mentioned markers were more frequently expressed on IR1 cells than IR1neg Tregs, the magnitude of the difference varied by marker, largely due to variable expression on IR1neg Tregs. Figure 2C shows the ratio of positive IR1 cells to IR1neg Tregs for each marker. Highest is CD62L, with a ratio of 10. CD62L is expressed by a median 76% (IQR 65 to 84) of IR1 cells, but on only 7.5% (IQR 4 to 13) of other Tregs ( Table 3).
Key suppressive markers are present on a high proportion of IR1cells. LAP is expressed by a median of 93% of IR1 cells compared to 12% of IR1neg Tregs. Similarly, IL-10 is found on 90% of IR1 cells and 17% of IR1neg Tregs ( Table 3). The constellation and concentration of known cell immune suppression markers on IR1 cells is strikingly and significantly different from IR1 neg Treg cells. These results were confirmed in purified and expanded Treg cultures as shown in Figure 3. Agonist TIRC7 Antibody Disproportionally Expands IR1 Cells Beyond Levels Achieved With IL-2, While Retaining the Suppressive Phenotype Prior work has shown that anti-TIRC7 agonist antibodies stimulate human CTLA4+ Tregs, while inhibiting Th1 and Th17 T-effector cells (20). An anti-TIRC7 IgG1 agonist antibody, humanized via the standard CDR grafting method (21) was selected based on binding affinity and specificity for TIRC7 (Supplementary Figure 3). It demonstrated specific binding to TIRC7 expressed in COS7 cells (Supplementary Figure 3A) or to wild type mice (+/+) but not to TIRC7 deficient mice splenocytes (-/-) and (Supplementary Figure 3B, left panel) with an affinity at 200 -300 pM. TIRC7 antibody was used to expand and isolate IR1 cells from purified Tregs obtained from 3 healthy subjects and to characterize the number of TIRC7+Tregs (IR1 cells) in the culture via flow cytometry. Incubation with this antibody plus IL-2 induced TIRC7+ IR1 Tregs to over 30%, substantially exceeding induction via IL-2 only ( Figure 3A). Stability of the IR1 Treg phenotype was examined for these subjects after 14 days expansion ( Figure 3B). High expression levels of LAP, CD39, GARP, FOXP3 and IL-10 were also maintained after two weeks expansion in IR1 cells ( Figure 3C).
To evaluate the overall immunosuppressive activity of the 14-days expanded and purified IR1 cells, we assessed their ability to inhibit cell proliferation in a mixed lymphocyte reaction (MLR) as compared to IR1neg Tregs. Human Teffector cells (Teff) and allogeneic dendritic cells (DC) were stimulated in an MLR under three conditions: (1) Teff + DC + IR1 cells; (2) Teff + DC +IR1neg Tregs; (3) Teff + DC (control). IR1 cells reduced proliferation by 80% compared to the control without Tregs, while IR1neg Tregs showed only a 50 percent reduction. Thus, IR1 cells show greater functional suppression compared to IR1neg Tregs ( Figure 3D, from left to right).

DISCUSSION
Tregs consist of a heterogeneous pool of cells and play an important role in limiting inflammatory processes. T-regulatory suppressive activity is one of the most powerful tools for modulating the immune system and is a recognized target for clinical intervention.
Here we highlight for the first time, the critical potential of IR1 cells as a distinct subset of Treg cells, defined by surface expression of the immune modulatory protein TIRC7. IR1 cells, make up some 5-10% of T-regulatory cells in healthy individuals and exhibit multiple phenotypic markers with distinct mechanisms of immune suppressive action. Flow cytometry panels used CD4+FOXP3+CD25+CD127lo staining by incorporating anti-TIRC7 antibodies to identify Tregs with surface expression of TIRC7.
Within non-activated Tregs, IR1 cells mapped to CD45RAhi and CD45RAlo subset, however with an increase in the CD45RAlo fraction. Expression analysis of TIRC7 (alias TCIRG1) as shared in gene expression databases, for human immune cell populations (Database of Immune Cell Expression, Expression Quantitative Trait Loci (eQTLs) and Epigenomics, www.dice-database.org) as well as Immgen (www.immgen.org) support our classification of TIRC7+Tregs to the resting and activated subsets of Tregs. The databases contain resting/naïve Treg populations and an activated/memory Treg population for gene expression analysis.
They use the same gating strategy for isolation (resting/naïve: CD4+, CD25 hi, CD127 lo, CD45RA+; activated/memory: CD4+, CD25 hi, CD127 lo, CD45RA-as used in our experiments. Our findings are in agreement with these databases which also show higher expression of TIRC7 in activated/memory Tregs compared to resting/naïve Tregs (DICE: mean of 185.59 to 71.62 in TPM, Immgen: normalized expression value of 373.143 to 217.560) isolated from human PBMC.
Flow cytometric analysis of the IR1+ subset, shows that they fall within the FOXP3hi compartment. FOXP3, the master regulator transcription factor, is responsible for restricting immune selfreactivity and suppressing excessive inflammation. FOXP3 acts by repression of gene transcription for IL-2 and other inflammatory cytokines, while activating suppressive pathways via transcription of IL-2RA, CTLA4, and the FOXP3 gene itself (22,23). FOXP3 expression is a determinant of immune homeostasis and is directly relevant to the stability of the cell lineage. Ablation of a conditional FOXP3 allele in mature Treg cells results in generation of "former" Treg cells that may acquire proinflammatory properties. Tregs are an actively dividing cell population with a critical role in containing immune-mediated inflammation. Ongoing Treg selfrenewal, combined with stable FOXP3 expression is essential to maintaining immune homeostasis (24) Tregs in peripheral blood express CD45RO, suggesting that these cells were previously activated and induced to proliferate. CD45RO cells are known to be extremely proliferative, with 20% in cycle at any given time compared to 2% of CD45RA naïve (resting) Tregs (25). IR1 cells map to the activated Treg subset, that manifests the highest proliferation and most suppressive properties (5). These finding are consistent with the previously described immune suppressive role of TIRC7 after T cell receptor activation.
In agreement with this notion, IR1 cells demonstrate superior inhibition of cellular proliferation in vitro. IR1neg Tregs, while much more numerous, are phenotypically heterogeneous and demonstrate less suppressive activity than IR1 cells.
Ex vivo incubation of lymphocytes with IL-2 yielded a 3.5-fold increase of IR1 cells, compared to a 1.3-fold increase in IR1neg Tregs at 72 h. The addition of TIRC7 agonist antibody led to a marked further shift towards IR1 cells.
The expanded IR1 cells continue to display the same high level of suppressive surface markers at 14 days as observed after 3-day activated cultures. IR1 cells expanded in the presence of the agonist TIRC7 antibody, maintain the potent suppressive phenotype reflected by the surface markers. It is plausible that differential expansion of IR1 cells also occurs in vivo (26). While low dose IL2 treatment expands the heterogenous Treg population, anti-TIRC7 antibody is likely to be highly selective in expanding IR1 cells. The importance of selective expansion of IR1 cells, is supported by the observation that the success of therapeutic models of heart transplant using agonist TIRC7 antibodies is associated with induction of suppressor pathways and inhibition of effector cells (27).
The IR1 cell phenotype is distinctive, with key surface markers occurring on a high percentage of IR1 cells, ranging from a median of 65.9% for CTLA4 to 93.0% for LAP. By contrast, for IR1neg Tregs, these markers range from a median of 7.5% for CD62L to 69.0% for CCR7 ( Table 3). Only CD45RO, does not differ, being present on a median of 98.3% of IR1 and 96.5% of IR1neg Tregs.
While each suppressive marker is significantly more frequent on IR1 cells compared to IR1neg Tregs, the degree of difference, expressed as the ratio of percent frequency, ranges from a high for CD62L of 10.2 to a low for CCR7 of 1.2. The potential impact of individual markers and combinations of markers is considered below.
CD62L and CCR7 both play a role in Treg homing to lymph nodes and sites of inflammation (28,29). CD62L is an important T cell homing receptor which orchestrates T cell trafficking of Tregs to secondary lymphoid organs. CCR7's multifaceted effects include its impact on the migration of lymphocytes to areas of inflammation (30,31). IR1 cells express both these markers: a median of 76.3% for CD62L and 81.4% for CCR7. However, activated IR1neg Tregs do not frequently express CD62L (median 7.5%) resulting in a high ratio (10.2) for IR1 to IR1neg Tregs. For CCR7 the picture is different since a median of 69.0% of IR1neg Tregs express CCR7. However, the combination of CD62L and CCR7 will be much greater for IR1 cells and would potentially increase homing characteristics (32). LAP+GARP+FOXP3+ Tregs are particularly effective in suppressing the proinflammatory effects of conventional T cells. Human LAP+GARP+FOXP3+ regulatory T cells attenuate xenogeneic graft versus host disease (33,34). Majority of IR1 cells express these markers, a median of 93.0% for LAP and for 78.1% for GARP. By contrast, on IR1neg Tregs, LAP is expressed by a median of 11.9% and GARP by a median of 28.9%. Thus, the combination of LAP and GARP should occur much more frequently on IR1 cells than IR1neg Tregs. The combination of LAP and GARP is thought to increase suppression of conventional T-cells. 25 IL-10 is specifically related to the inhibition of proliferation in MLC. It plays an important role in the suppressive function of antigen specific, induced Tregs through its effects on dendritic cells (23,35). A median of 90.3% of IR1 cells express IL-10 compared to 17.3% of IR1neg Tregs. Mixed lymphocyte cultures with IR1 cells secreted high levels of IL-10. Such secretion was not seen for IR1neg Tregs.
CTLA-4 inhibits dendritic cell maturation, a core mechanism of T regulatory cell mediated suppression. The co-stimulatory and co-inhibitory molecules CTLA-4 and ICOS are involved in the pathogenesis of autoimmune disease (36,37). TIRC7 is involved in regulation of CTLA-4, and its activation leads to increased CTLA-4 expression (11,38,39). IR1 cells show higher expression of both CTLA-4 and ICOS than do IR1neg Tregs. CTLA-4 is expressed by a median of 65.9% (of IR1 cells compared to 13.7% of IR1neg Tregs. The ratio of median percent cell expression for CTLA-4 is 4.81. ICOS is expressed by 88.8% of IR1 cells compared to 39.3% of IR1neg Tregs with a resultant ratio of nearly 2.
HLA-DR+ Teff cells expressed significantly higher levels of Th1/Th17 cytokines that may regulate Treg function through a reciprocal counter-balancing relationship. Activated HLA-DR +CD4+ T cells may contribute to inflammation by compromising Treg-mediated suppression. IR1 cells provide potent inhibition of Teff activation via enriched expression binding to HLA-DR + Teff cells. Most IR1 cells express HLA-DR: a median of 87.5%. By contrast a median of 28.6% IR1neg Tregs are HLA-DR+, resulting in a ratio of 3.6.
Two major subsets of Treg cells have been described in vivo; thymus derived Treg (tTreg) cells, which develop in the thymus, and peripherally induced Tregs (pTreg). Helios, a member of the Ikaros transcription factor family, is expressed in 60-70% of Tregs and is believed to be a marker of thymus derived Tregs which are stable and highly suppressive. The presence of Helios influences Treg stability and function (26). For IR1 cells the median Helios expression is 91.5% compared to 44.9% for IR1neg Tregs, a ratio of 2.04.
CD39, an ectonucleotidase, which hydrolyses proinflammatory ATP, is regarded as a marker of highly active and suppressive T regulatory cells. Recent studies have suggested that catalytic inactivation and conversion of the extracellular ATP and ADP to AMP, both induced by CD39, serve as antiinflammatory mechanisms by which Tregs mediate immune suppression in human autoimmune diseases. Median expression of CD39 on IR1 cells was 86.0%, significantly higher than 47.5% on IR1neg cells, with a resulting ratio of 1.81.
In vitro suppression assays reflect cell suppressive activity in vivo, with networks of pathways working separately but in parallel, to achieve suppression. A classic example is Treg cell-mediated suppression in mixed lymphocyte reactions. In this manuscript we have shown that IR1 cells reduce lymphocyte proliferation in MLR by over 80%, versus less than 50% for IR1neg Tregs ( Figure 3B). The frequency of IR1 cells in peripheral blood is narrowly maintained at a low level, with a mean of 8 per 10,000 PBMCs. IR1 home to sites of inflammation, and the in vivo expansion of IR1 cells, directly or indirectly will multiply this effect.
As shown in Figure 3A, co-culture of CD25+ CD4+ T cells with the agonist TIRC7 antibody for 14 days, triggered additional induction of IR1 cells beyond IL-2 alone. These TIRC7+ cells showed high, stable expression of LAP, CD39, IL-10, GARP and FOXP3, underlining the antibody's ability to expand and still maintain the phenotype. The agonist antibody not only expands IR1 cells, but the expanded cells over weeks maintain a stable and suppressive phenotype.
However, CD4+CD25+CD127loFOXP3+ Tregs, are heterogeneous, with different phenotypic and functional characteristics. Although polyclonal Treg treatments have been promising in terms of safety, the efficacy of such Treg therapy has been inconsistent. This may reflect the heterogeneity of the Treg cells, not all of which are stable or immune suppressive. Ultralow dose IL-2 has been used in vivo to selectively expand Treg expressing high affinity IL-2 receptors. This approach has been well tolerated in various disorders (40).
Studies in diverse indications suggest a therapeutic potential for Tregs in autoimmune disease and solid organ transplantation (TRACT). To work effectively, adoptively transferred Tregs must migrate to and survive within the inflamed tissue. The safety and liver-homing properties of GMP grade autologous Tregs have been demonstrated in patients with autoimmune hepatitis (41) and shown Tregs migrated to liver suggesting autoimmune liver diseases. Based on their phenotypic markers, IR1 cells are expected to be found at sites of inflammation. In fact, data from an ongoing study displayed IR1 cells in human autoimmune samples (unpublished data, manuscript in preparation). TIRC7 positive cells are rare in peripheral blood and concentrated in mesenteric lymph nodes and small intestinal sub-mucosa as shown by Wakkach et al. (19) Despite the different phenotype between mice and human IR1 cells it has been shown that murine IR1 type cells express high amounts of IL-10 and exhibit a highly inhibitory Tr1 phenotype (19).
The IR1 cell subset of Tregs is stable, relatively homogeneous and demonstrates a highly suppressive phenotype. These cells can be readily induced, expanded and isolated and have therapeutic potential in a wide range of indications. In healthy subjects the ratio of IR1 cells to PBMC lies within a narrow range. IR1 cells can use multiple immune suppressive tools such as cell-cell contact inhibition via CTLA4, direct cytotoxicity via CD39 and inhibition of proliferation via soluble mediators such as IL-10. High levels of CD62L and CCR7 can direct IR1 cells to lymphatic tissue and areas of inflammation. IR1 cells may play the role of a readily mobilizable population in the peripheral blood that can be dispatched to areas of excessive immune activation. IR1 cells in the peripheral circulation constitute a rapidly inducible "ready-to-go" population. Expanded IR1 cells remain stable and express similar levels of activation markers on their surface for some weeks. IR1 cells are found among non-activated CD45RAhi cells as well as CD45RAlo Tregs, an observation that supports the presence of a specific lineage defined by TIRC7 expression. Non-activated CD45RAlo IR1 cells show marked expression of suppressive molecules. However, the differential expression of the suppression markers between IR1 and IR1neg Tregs is most pronounced after activation. After IL-2 activation, respective markers are expressed on 66-93% of IR1 cells. For the IR1neg population, expression is dramatically lower for each molecule measured (Figure 2A). It is plausible that circulating IR1 cells, armed with a cargo of suppressive markers, are deployed to sites of immune activation and play a key role in maintaining immune homeostasis in inflamed tissue. By contrast, the potential impact of highly suppressive cells is limited physiologically by maintaining low numbers of IR1 cells in the peripheral circulation. IR1 cells have the potential to restore immune homeostasis in diseases that are characterized by inadequate T regulatory cell activity. This approach has the potential to modify disease natural history without requiring ongoing immune suppressive treatment. Amplification of autologous IR1 cell activity, can suppress excess T effector cell activity directed at a specific target. Autoimmune diseases (e.g., Type 1 diabetes, autoimmune liver diseases) as well solid organ transplant are potential indications for IR1 cell therapy.
A high level of immune suppression is achieved by IR1 cells, possibly through its ability to use multiple mechanisms, such as inhibition of activation via cell-cell contact, soluble mediators, or direct induction of apoptosis. Thus, both, antibody targeting of TIRC7 or cell therapy using IR1 cells, offer disease depended distinct therapeutic options.
While the healthy subject cohort studied is not large, the characteristics of IR1 cells are quite consistent. Subjects were identified by a "convenience sample" that was not diverse or representative, particularly with respect to age. It is not yet known whether IR1 cells from pediatric or geriatric populations will show similar features. IR1 cells studied were derived from peripheral blood. Such TIRC7+ Tregs can be seen in histopathological samples from various autoimmune diseases (data on file). In addition, characteristics of IR1 cells in subjects with acute or chronic diseases are currently under study with the goal of unlocking the therapeutic potential of IR1 cells.

Subjects
22 healthy Caucasian donors participated, 12 female and 10 males, mean age 24.9 years.

Ethics Statement
Collection of blood from healthy volunteers and tissues from patients was performed after approval by the local ethical committee and signed informed consent (ChariteÚ niversitätsmedizin, reference number EA2/095/18).

Peripheral Blood Mononuclear Cell Isolation
Peripheral blood was collected in four 10ml BD vacutainer EDTA tubes from each enrolled subject and processed immediately. PBMC were isolated using Ficoll density gradient centrifugation. The blood was transferred into two 50ml Falcon tubes and diluted with 15ml PBS per tube to increase purity. The diluted blood was then carefully layered on top of 15ml Ficoll Plaque solution and centrifuged at 4°C, for 20 minutes at 300g without a break. Due to the different densities of the components, the suspension separates, and the leukocytes form a distinct layer between the plasma and Ficoll layer. After pipetting 10ml of the overlaying plasma, PBMCs were isolated using a 7ml plastic transfer pipette. ACK-lysis buffer was then added, and the suspension was centrifuged. Cells were counted with a Neubauer counting chamber and seeded in a 96-well plate.

Humanized Antibody Generation
TIRC7 mAb was humanized via CDR grafting (42) and characterized for specificity, affinity (unpublished, Nekonal Sarl, data on file) and purified antibody 10 µl/ml was used for expansion cultures.

Treg Isolation
The experiments were performed using the Human CD4+ CD25+ Regulatory T Cell Isolation Kit, from Miltenyi. Freshly isolated PBMCs were centrifuged for 10 minutes at 300g. The supernatant was discarded, and the cell pellet resuspended in 90µl MACS buffer. 10µl of CD4+ T Cell Biotin-Antibody cocktail was added, and cells incubated for 5 minutes in the refrigerator. 20µl Anti-Biotin Microbeads were applied and incubated for 10 minutes. To isolate CD4+ from CD4-cells, magnetic depletion separation using an LD column was performed. CD4+ cells were then collected in the effluent, while CD4-cells remained in the column. The effluent was collected and centrifuged for another 10 minutes at 300g. After aspirating the supernatant, the cell pellet was resuspended in 90µl buffer, and 10µl CD25 microBeads were added and incubated for 15 minutes in the dark, in the refrigerator. Cells were then magnetically separated and positively selected by using an MS-column.

Proliferation Assay
After 5 days, per well, 20 µl of the BrdU labelling reagent diluted 1:100 in MLR-assay medium were added to each well to reach a final BrdU dilution of 1:1,000. The cells were incubated for another 16h at 37°C and 5% CO2. After the second incubation, the 96 well plate was centrifuged (300 g, 4 minutes, 4°C) and the supernatant discarded. The proliferation assay was performed using a commercial kit by Roche (11647229001) according to the manufacturers protocol. Finally, 10 µl stop solution was added per well and the optical density at 450 nm was measured using the SUNRISE ™ Microplate Reader by Tecan.

Flow Cytometry
Analysis was performed at two different timepoints to examine distinct activation levels of Treg (t0resting Treg, t72hactivated Treg). 2x10 5 freshly isolated PBMCs per well were Fc-blocked (5µl/well), stained with TIRC7 mAb3 (FITC, antimouse, 20µg/ml) for 1h at room temperature (RT) in the dark and then incubated with the extracellular antibodies CD3 . After 30 minutes, the well plates were centrifuged (300g, 4 minutes, 4°C), supernatants were discarded, cell pellets resuspended in 100µl per well of the master mixes and incubated for 20 more minutes, as above. Processed PBMCs were washed with 200µl MACS buffer and then fixed and permeabilized following the BioLegend Fix/Perm buffer set protocol to stain the intracellular markers FOXP3 (PE, BV421), IL-10 (PE) and Helios (APC) for 20 minutes in the dark at RT (see Supplemental data for panels and antibodies). After 2 washing steps, the cell pellet was resuspended in 200µl MACS buffer, and the samples were then measured using the BD LSR Fortessa. For cytokine analysis Golgi inhibitor Brefeldin A 1000X was added to the cells in culture at a concentration of 1X (diluted in culture medium) according to manufacturer's protocol (Biolegend) 6 hours before harvesting and staining for flow cytometric analysis.
Stopping gates were set on live cells, 1x10 5 live cells after isolation and 2-5x10 4 after in vitro stimulation. To ensure the correct gating for TIRC7, fluorescence minus one (FMO) control without TIRC7 mAb was used for each Treg panel. To compensate for spectral overlaps between different fluorophores, samples were single stained with each antibody. Data reproducibility and instrumental quality control was achieved by acquisition of cytometer Setup &Tracking beads from BD and 8 peak Rainbow Calibration Beads from BioLegend. FACS data was analyzed using FlowJo 10.7.1 Software. Treg and their subsets were identified as reported) (see Supplemental data for gating). Treg count, TIRC7+/-Treg count, marker expression on the respective subsets and MFI (mean fluorescent intensity) were analyzed.
Wild types and TIRC7 knockout mice splenocytes were fixed for 20 min at 4°C with 4% paraformaldehyde in PBS and permeabilized. Cells were incubated overnight at 4°C with anti-TIRC7 antibody (10µg/ml) or with anti-human IgG (hIgG, 5µg/ ml, Sigma) as negative control. Cells were rinsed with PBS, and incubated with Cy3-conjugated goat anti-human IgG (1:250, Sigma) diluted in 5% milk/PBS. Cells were mounted with 50% (vol/vol) glycerol in PBS and confocal images were obtained by using Zeiss LSM 510 confocal laser scanning microscope.

Statistical Analysis
Data analysis was performed using GraphPad Prism 8 software. The phenotypical differences between IR1 and IR1neg Tregs were assessed using the non-parametric Wilcoxon matched pairs signed rank test to compare percentage marker expression on IR1 and IR1neg from 72h IL-2 in vitro stimulated PBMCs from 8 healthy volunteers.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Ethical Comittee Charite. The ethics committee waived the requirement of written informed consent for participation.

AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.  (B). TIRC7 protein was not detected in TIRC7 knockout mice (-/-) splenocytes in comparison to wild type (+/+) using TIRC7 mAb. (C) Biacore SPR analysis performed in varying concentrations to determine the kinetic constants or absorption effects as shown for mAb1.